Understanding the interplay between age-related inflammatory diseases and CH may result in personalized therapeutic opportunities, as in the case of CANTOS trial, where carriers of TET2 mutations were more likely to benefit from interleukin-1β (IL-1β) inhibition for secondary CVD prevention (14). Here, TET2 is linked to cyclic hematopoiesis.